Dimerix Limited · ASX:DXB
Dimerix — Monsoon Twilight Investor Briefing, Melbourne 2024
19 slides from Dimerix's conference presentation, Jun 13, 2024
Slide 1: Dimerix to present at Melbourne Twilight Investor Briefing
Immediate Release DIMERIX TO PRESENT AT MELBOURNE TWILIGHT INVESTOR BRIEFING MELBOURNE, Australia, 13 June 2024: Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company with late-stage clinical assets, is pleased to advise that CEO and Managing Director, Dr Nina Webster, will be prese
Slide 2: About DMX-200 and About FSGS
About DMX 200 DMX 200 is the adjunct therapy of a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker - the standard of care treatment for hypertension and kidney disease. DMX 200 is protected by granted patents in various
Slide 3: FSGS Clinical Study Twilight Briefing
ACTING FSGS CLINICAL STUDY @ Dimerix (ASX:DXB) al use only 513 June 2024 “Twilight Briefing LE Developing new therapies to treat inflammatory causes of kidney and respiratory disease with unmet clinical needs Authorised for lodgement by the Board of the Company
Slide 4: Forward looking statements
Forward looking statements nis presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks on important factors that may cause the actual results, performance or achievements of Dimerix to be materially different from
Slide 5: Corporate overview
Corporate overview SHARE PRICE 0.7 50 For personal use only -Volume (m) -Share Price Adj Close 45 T icker Symbol ASX:DXB 0.6 40 � 0.5 1 E 35 � 30 � Proforma Cash Balance (Mar24) NA$35.2 million � 25 � 20 � 0.2 15 � i I Ii 11 111111 ,j L � ,. l L 1.11111 ,W J 111 t 1,1,l1 11I 1 1111 111 1,11,i 11 111
Slide 6: Lead Drug Candidate
Lead Drug Candidate For personal use only • • FSGS Indication • • • Commercial Validation •
Slide 7: What is FSGS?
What is FSGS? For personal use only Why are kidneys important? Why is proteinuria important?
Slide 8: Progression of FSGS kidney disease
Progression of FSGS kidney disease For personal use only Existing blood pressure medication targets Step 1: angiotensin receptor blocker (ARB) lowers blood pressure N Less kidney cells cause further hyperfiltration and inflammation Kidney vessels have to work harderunder highypressure 1 DMX-200 inte
Slide 9: DMX-200: Phase 2 met primary and secondary endpoints
DMX-200: Phase 2 met primary and secondary endpoints >f Clinically meaningful outcomes achieved for patients,? with no safety issues q 12) > y reduction in —_ 6 proteinuria could yield years oO _ VK of preserved native kidney Cc iL function and delay the [e) R- gh onset of kidney failure and 7 re y
Slide 10: DMX-200: 17% average reduction of proteinuria is clinically meaningful
DMX-200: Phase 2 met primary and secondary endpoints >f 17% average reduction of proteinuria in Phase 2 is clinically meaningful! EUROPEAN MEDICINES AGENCY Estimated eGFR TENCE MEDICINES 1 om Adjusted models fo) ; slope year year uPCR reduction (@5%Cl FDA & EMA recognise surrogate o Persistent prote
Slide 11: Phase 3 Clinical Trial
PHASE 3 CLINICAL TRIAL For personal use only @ Dimerix
Slide 12: Background Phase 3 Trial Timeline
For personal use only Background Phase 3 Trial Timeline • • •
Slide 13: For personal use only
• • • • • • • For personal use only
Slide 14: FSGS Market Opportunity
FSGS MARKET OPPORTUNITY For personal use only @ Dimerix
Slide 15: Potential FSGS market size
Potential FSGS market size No approved therapies for F Multi-billion dollar market potential y Fowperspnal Example pricing for other rare kidney disease drugs : * in the US (i.e. Filspari in IgAN)?is US$9,900 p/month * in Europe/UK (i.e. Kinpeygo/Tarpeyo)? is US$8,267 p/month (€7,630) Example annual
Slide 16: Summary of DMX-200 licensing deals
Summary of DMX-200 licensing deals Dimerix has validated the technology! and proven its ability to licence multiple territories, with more deals anticipated Summary ADVANZ & PHARMA pear) Other Licensing Deals (incl. US & China) For personal use sales Escalating mid-teen-20% EEA, Canada, Switzerland,
Slide 17: Global partnering availability
Global partnering availability + Licensing deal second of potentially multiple agreements globally + Received multiple non-binding term sheets for global deals and regional deals! + Multiple parties in data room conducting due diligence and negotiating for various territories! 9 avtovrs [REPAGERMANI
Slide 18: Summary: lead candidate, market opportunity and upcoming milestones
Lead Drug Candidate • For personal use only • FSGS Indication • • • Market Opportunity • • • o Commercial Validation • • Upcoming FSGS Milestones • •
Slide 19: Well positioned to deliver our strategic plan
For personal use only A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases. WELL POSITIONED TO DELIVER OUR STRATEGIC PLAN ESG Statement SCAN ME Dimerix HQ 425 Sm
Dimerix — Monsoon Twilight Investor Briefing, Melbourne 2024 on 6ix